No­var­tis ties up with the vir­tu­al biotech Parvus to try a new ap­proach on Type 1 di­a­betes

Parvus CEO Jan­ice LeCocq

No­var­tis has turned to a small, vir­tu­al biotech in Cana­da for some fresh in­spi­ra­tion on how it might one day de­feat Type 1 di­a­betes.

The phar­ma gi­ant’s No­var­tis In­sti­tute of Bio­med­ical Re­search now has the ex­clu­sive li­cense to use Parvus Ther­a­peu­tics’ plat­form for di­a­betes, com­ing in with an un­spec­i­fied pack­age of mile­stones, an up­front, re­search sup­port and an eq­ui­ty stake to seal the deal.

That’s a very big deal for Parvus, which has been op­er­at­ing for the last few years on about $20 mil­lion in re­search grants and $5 mil­lion in an­gel in­vest­ments with a few full-time staffers to guide the work be­ing done in Pere San­ta­maria’s lab at the Uni­ver­si­ty of Cal­gary.

San­ta­maria, the CSO and founder at Parvus, was run­ning an imag­ing ex­per­i­ment us­ing nano-sized bits of iron ox­ide when he made a serendip­i­tous dis­cov­ery. As he went on to lat­er write in Na­ture:

(S)ys­temic de­liv­ery of nanopar­ti­cles coat­ed with au­toim­mune­ dis­ease ­rel­e­vant pep­tides bound to ma­jor his­to­com­pat­i­bil­i­ty com­plex class II (pMHCII) mol­e­cules trig­gers the gen­er­a­tion and ex­pan­sion of anti­gen­spe­cif­ic reg­u­la­to­ry CD4+ T cell type 1 (TR1)­like cells in dif­fer­ent mouse mod­els, in­clud­ing mice hu­man­ized with lym­pho­cytes from pa­tients, lead­ing to res­o­lu­tion of es­tab­lished au­toim­mune phe­nom­e­na.

Those re­pro­grammed reg­u­la­to­ry T cells were able to stop the au­toim­mune at­tack – in mice – with­out flat­ten­ing the im­mune sys­tem.

That’s what got No­var­tis’ in­ter­est.

Jay Brad­ner, NI­BR

“There had been in­for­mal con­tacts with No­var­tis fair­ly ear­ly on in the life of the com­pa­ny,” CEO Jan­ice LeCocq told me.

San­ta­maria’s first pa­per on this was pub­lished in 2010 with the sec­ond ap­pear­ing last year, and he’s been work­ing in the lab for years to com­plete the pre­clin­i­cal work need­ed to get an IND ready for the FDA, he says. A joint com­mit­tee with No­var­tis will now over­see that step, with the phar­ma gi­ant tak­ing charge of the clin­i­cal pro­gram.

LeCocq isn’t pro­vid­ing any time­lines on de­vel­op­ment right now.

Like a lot of vir­tu­al biotechs, Parvus de­pends on a net­work of con­sul­tants for much of the heavy lift­ing that needs to get done at the com­pa­ny. And now with No­var­tis’ sup­port the team will al­so get to start adding a de­vel­op­ment group, which can turn to one of the oth­er po­ten­tial au­toim­mune dis­ease tar­gets on the menu for their tai­lored Navacims.

Mul­ti­ple scle­ro­sis is the fur­thest along on that list, but LeCocq says they have made no fi­nal de­ci­sions on what Parvus will turn to next as NI­BR fo­cus­es on Type 1 di­a­betes.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News writer Nicole DeFeudis has posted a snapshot of all the companies, universities and hospital-based groups now racing through the clinic, ranking them according to their place in the pipeline as well as the latest remarks available on timelines. And we’ll keep this lineup updated right through the end of the year, as the checkered flags start to fall, possibly as early as October.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

The Cell and Gene Industry is growing at a staggering 30% CAGR and is estimated to reach $14B by 20251. A number of cell, gene and stem cell therapy sponsors currently have novel drug substances and products and many rely on Contract Development Manufacturing Organizations (CDMO) to produce them with adherence to stringent regulatory cGMP conditions. Cell and gene manufacturing for both autologous (one to one) and allogenic (one to many) treatments face difficult issues such as: a complex supply chain, variability on patient and cellular level, cell expansion count and a tight scheduling of lot disposition process. This complexity affects quality, compliance and accountability in the entire vein-to-vein process for critically ill patients.

Stéphane Bancel speaks to President Donald Trump at the White House meeting on March 2 (AP Images)

UP­DAT­ED: Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine con­tracts

The US pre-order for Moderna’s Covid-19 vaccine is in.

Operation Warp Speed is reserving $1.525 billion for 100 million doses of Moderna’s Phase III mRNA candidate, rounding out to about $15 per dose — including $300 million in incentive payments for timely delivery. Given that Moderna has a two-dose regimen, it’s good for vaccinating 50 million people. The US government also has the option to purchase another 400 million doses for a total of $6.6 billion, or $16.5 per dose.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)

UP­DAT­ED: Bris­tol My­ers Squibb com­mits $300 mil­lion to com­bat racial dis­par­i­ties, but de­clines to re­lease own de­mo­graph­ic da­ta

After the police killing of George Floyd, a flurry of pharma and biotech companies, executives and investors jumped out to make statements, either expressing support for Black Lives Matter and the protests or condemning systemic racism.

Now, a Big Pharma company is publicly putting some teeth behind those statements. This morning, Bristol Myers Squibb announced they would spend $300 million on a broad effort to reduce racial health disparities, and diversify both their clinical trials and their own executive team and workforce.

Martin Shkreli (AP Images)

Mar­tin Shkre­li's in­fa­mous Dara­prim falls off top 20 most ex­pen­sive drugs list

Martin Shkreli incited a national uproar five years ago when he raised the price of Daraprim by a factor of 56 essentially overnight from $13.50 to $750 per pill. Now that the “Pharma Bro’s” high-priced project has received a generic, it no longer places among the most expensive drugs in the world.

GoodRx is back with the latest update of the top 20 most expensive drugs and Daraprim’s exclusion marks the biggest change. The drug had previously ranked seventh on the list’s last iteration, which came in February before the world went into quarantine. Another of Shkreli’s former companies, Retrophin, saw its Chenodal drug place in the top 10 again.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

UP­DAT­ED: Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,400+ biopharma pros reading Endpoints daily — and it's free.

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups.

On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind.

Eisai moves to 200 Metro Blvd. by late 2021 (ON3)

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

Eight years after Roche pulled up stakes from Nutley, NJ in a major R&D reorganization, Japan’s Eisai is moving its US corporate and research hub into their old campus.

Now the ON3 property, Eisai — a longtime Biogen partner focused on neurodegenerative disorders like Alzheimer’s — will bring together a staff of up to 1,200 employees. And execs are pitching the move to the New Jersey campus as a cultural game-changer.

VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

VBL Therapeutics announced that it is on track in a Phase III trial of its drug VB-111 (ofranergene obadenovec) to treat platinum-resistant ovarian cancer in combination with paclitaxel.

After conducting its second interim analysis, the independent Data Safety Monitoring Committee (DSMC) recommended that Israel-based VBL continue full steam ahead. The committee looked at unblinded overall survival rate, which is the primary endpoint of the study, dubbed OVAL. The first analysis evaluated CA-125 response.